Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Filed Aug 8, 2014 · 10-Q · 39 days after period end · 0001193125-14-301873
| Metric | Q2 2014 | Q2 2013 | Q2 2012 | Q2 2011 |
|---|---|---|---|---|
| Net Income | -$44.07M | -$18.17M | -$12.96M | -$13.82M |
| EPS Diluted | -$0.58 | -$0.29 | -$0.25 | -$0.33 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 8, 2014 · 39 d after period end
